These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 7515268

  • 1. FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report.
    Visani G, Tosi P, Zinzani PL, Manfroi S, Zaccaria A, Testoni N, Lemoli RM, Rosti G, Pelliconi S, Tura S.
    Br J Haematol; 1994 Feb; 86(2):394-6. PubMed ID: 7515268
    [Abstract] [Full Text] [Related]

  • 2. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
    Martinelli G, Testoni N, Zuffa E, Visani G, Zinzani PL, Zaccaria A, Farabegoli P, Arpinati M, Amabile M, Tura S.
    Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
    [Abstract] [Full Text] [Related]

  • 3. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
    Fleischhack G, Hasan C, Graf N, Mann G, Bode U.
    Br J Haematol; 1998 Aug; 102(3):647-55. PubMed ID: 9722289
    [Abstract] [Full Text] [Related]

  • 4. Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG).
    Tedeschi A, Montillo M, Ferrara F, Nosari A, Mele G, Copia C, Leoni P, Morra E.
    Eur J Haematol; 2000 Mar; 64(3):182-7. PubMed ID: 10997884
    [Abstract] [Full Text] [Related]

  • 5. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.
    Turk J Pediatr; 2000 Mar; 42(3):198-204. PubMed ID: 11105617
    [Abstract] [Full Text] [Related]

  • 6. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU, Khan B, Ahmed P, Raza S, Hussain I, Mahmood A, Iqbal H, Malik HS, Anwar M.
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [Abstract] [Full Text] [Related]

  • 7. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
    Katagiri T, Miyazawa K, Uchida Y, Hayashi S, Iwama H, Shyohji N, Kawakubo K, Shimamoto T, Inatomi Y, Kuriyama Y, Yaguchi M, Nehashi Y, Ohyashiki K, Toyama K.
    Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
    Higashi Y, Turzanski J, Pallis M, Russell NH.
    Br J Haematol; 2000 Nov; 111(2):565-9. PubMed ID: 11122104
    [Abstract] [Full Text] [Related]

  • 10. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
    Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, Rezvani K, Craddock C, Rassam S, Prentice HG.
    Br J Haematol; 2001 Dec; 115(3):622-9. PubMed ID: 11736947
    [Abstract] [Full Text] [Related]

  • 11. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
    Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH, Peters GJ, Noordhuis P, Muus P, Selleslag D, van der Holt B, Delforge M, Löwenberg B, Verhoef GE, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
    Blood; 2004 Apr 15; 103(8):2908-13. PubMed ID: 15070662
    [Abstract] [Full Text] [Related]

  • 12. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
    Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, Clavio M, Cenacchi A, Gamberi B, Carrara P.
    Leukemia; 1994 Nov 15; 8(11):1842-6. PubMed ID: 7526088
    [Abstract] [Full Text] [Related]

  • 13. Purine nucleoside analogues in the treatment of myleoid leukemias.
    Robak T.
    Leuk Lymphoma; 2003 Mar 15; 44(3):391-409. PubMed ID: 12688309
    [Abstract] [Full Text] [Related]

  • 14. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec 15; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 15. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Dec 15; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 16. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S.
    J Clin Oncol; 1994 Apr 15; 12(4):671-8. PubMed ID: 7512125
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen.
    Tafuri A, De Felice L, Petrucci MT, Mascolo MG, Ricciardi MR, Ciliberti C, Martelli MP, Petti MC.
    Cytokines Mol Ther; 1995 Dec 15; 1(4):301-7. PubMed ID: 9384683
    [Abstract] [Full Text] [Related]

  • 20. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M.
    Cytokines Mol Ther; 1995 Mar 15; 1(1):21-8. PubMed ID: 9384660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.